Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3404974 | 0.88 | KCNH2 (0.41) | KCNH2 | |
| SCHEMBL1838608 | 0.83 | KCNH2 (0.39) | KCNH2 | |
| SCHEMBL3427897 | 0.81 | KCNH2 (0.36) | KCNH2 | |
| SCHEMBL3782875 | 0.78 | CYP1A2 (0.31) | — | |
| SCHEMBL3410398 | 0.78 | CYP1A2 (0.31) | — | |
| SCHEMBL29050378 | 0.78 | KCNH2 (0.42) | KCNH2 | |
| SCHEMBL1723676 | 0.75 | KCNH2 (0.47) | KCNH2 | |
| SCHEMBL1723353 | 0.75 | KCNH2 (0.47) | KCNH2 | |
| SCHEMBL14400284 | 0.74 | KCNH2 (0.43) | KCNH2 | |
| SCHEMBL29050345 | 0.74 | KCNH2 (0.45) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2721034-B1 | N-HETEROTRICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2016-07-20 | — | — | EP | disclosed |
| US-9321788-B2 | Tricyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2016-04-26 | — | — | US | disclosed |
| US-20140235855-A1 | Tricyclic Antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2014-08-21 | — | — | US | disclosed |
| EP-2721034-A1 | TRICYCLIC ANTIBIOTICS | Basilea Pharmaceutica AG (CH) | 2014-04-23 | — | — | EP | disclosed |
| US-8466168-B2 | Tricyclic alkylaminomethyloxazolidinone derivatives | Actellon Pharmaceuticals Ltd. (CH) | 2013-06-18 | — | — | US | disclosed |
| WO-2012171860-A1 | TRICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2012-12-20 | — | — | WO | disclosed |
| EP-2321307-B1 | TRICYCLIC ALKYLAMINOMETHYLOXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-12-19 | — | — | EP | disclosed |
| US-20110136795-A1 | TRICYCLIC ALKYLAMINOMETHYLOXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. | 2011-06-09 | — | — | US | disclosed |
| EP-2321307-A1 | TRICYCLIC ALKYLAMINOMETHYLOXAZOLIDINONE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010015985-A1 | TRICYCLIC ALKYLAMINOMETHYLOXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235855-A1 | Tricyclic Antibiotics | CBR1, CYP2S1, C1S | KCNH2 1248/4885 |
| US-20110136795-A1 | TRICYCLIC ALKYLAMINOMETHYLOXAZOLIDINONE DERIVATIVES | PYM1, Q6ZSR9, O60361 | KCNH2 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.